University of Michigan researchers identify CDK12 gene mutation driving aggressive prostate cancer, develop oral degrader targeting CDK12 and CDK13 for potential clinical trials.

Researchers at the University of Michigan Rogel Cancer Center have identified a mutation in the CDK12 gene that drives aggressive prostate cancer. They developed an oral degrader targeting CDK12 and the related CDK13 gene, showing promise in lab tests for halting tumor growth. This treatment is still in the pre-clinical stage, with plans to advance it toward clinical trials, potentially enhancing treatment when combined with existing therapies.

October 04, 2024
13 Articles

Further Reading